United Kingdom : Edinburgh - Pharmaceutical products
Supply of ambrisentan tablets to NHS Scotland.
Legal, economic, financial and technical information
(a) potential framework participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered goods at the date of submission of the tender.
(b) potential framework participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) all tendered Goods must comply with the MHRA best practice guidance on labelling and packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design.
(a) confirmation of existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered goods at the date of submission of the tender should be included in the qualification envelope of the ITT under the technical and professional ability: quality control.
(b) confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the qualification envelope of the ITT under the quality assurance schemes.
(c) confirmation that samples for tendered goods will be supplied upon request to ensure compliance with the MHRA best practice guidance on labelling and packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design. Confirmation of sample provision should be provided in the qualification envelope of the ITT under technical and professional ability: products.
Sheriff Court House
27 Chambers Street
The estimated value referred to in Section II.1.5) and II.2.6) covers the thirty (30) month contract duration and the eighteen (18) month extension period of the framework agreement.
The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 35795. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343
The contracting authority does not intend to include a sub-contract clause as part of community benefits (as per Section 25 of the Procurement Reform (Scotland) Act 2014) in this contract for the following reason:
It is not envisaged that sub-contractors will be utilised in delivery of this framework agreement.
The contracting authority does not intend to include any community benefit requirements in this contract for the following reason:
No Community Benefits will be deliverable through the award of this framework agreement.
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.Main CPV code 33600000
18 Aug 20200 days remaining
Total estimated value
GBP 5.0 million
United Kingdom, Edinburgh
LOTS ASSOCIATED WITH THIS TENDER
GBP 5.0 million
Supply of ambrisentan 5 mg and 10 mg tablets (in various pack sizes) to NHS Scotland.
Goods are forecast to be supplied to patients predominantly via the Homecare route with nominal exception (0.004 %). There is a requirement for framework participants to supply goods to the nominated homecare suppliers.
The authority intends to award this framework as a single supplier framework per line.
Full details of goods and volumes can be found within the ITT documents.
Main site or place of performanceAll entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
Description of renewalsThis framework includes the option to extend for up to a total period of eighteen (18) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
Ireland : Naas - Pharmaceutical productsIreland
Value: 1 Euro
Norway : Lillestrøm - Cleaning and polishing productsNorway
Value: 71.0 million Norwegian Krone
United Kingdom : Normanton - Personal care productsUnited Kingdom of Great Britain and Northern Ireland
Value: 395.2 million Pound Sterling
Norway : Oslo - ScannersNorway
Value: 1.5 million Norwegian Krone
Germany : Berlin - Personal care productsGermany
Value: Not specified
Malta : Floriana - Medicinal products used in diabetesMalta
Value: Not specified
United Kingdom : Edinburgh - Orthopaedic implantsUnited Kingdom of Great Britain and Northern Ireland
Value: 15.0 million Pound Sterling